> University Research Staffback
Dr. NG Kwong Man
Research Assistant Professor
Dr. Kwong-Man Ng obtained his Ph.D degree in the Department of Zoology (now as part of the school of biological science), The University of Hong Kong in 2006. He has been working as visiting scholar in the University of Western Ontario and the University of British Columbia and received post-doctoral training on Human Stem Cell biology in the University of California, Davis, and the Departments of Physiology and Medicine, the University of Hong Kong. Currently, he is working as a Research Assistant Professor at the cardiology division, the Department of Medicine, The University of Hong Kong. His research focuses on the biotechnological and clinical applications of human pluripotent stem cells in the studies of inherited cardiac disorders. Owing to the lack of human cardiomyocyte-based cellular models, the study of the pathogenic mechanism associated with particular gene mutation have been a challenging task. To date, with the advancement in the induced pluripotent stem cells (iPSCs) technology, terminally differentiated somatic cells from patients carrying specific cardiomyopathy-associated mutations can be reprogrammed into iPSCs and subsequently differentiated into functional cardiomyocytes. This offers a new approach for modeling human inherited cardiac disorders (Figure 1). In recent years, Dr. Ng and colleagues in the cardiology division has generated various iPSCs lines from the patients suffered from different types of cardiomyopathies, these studies not only provided new insights on the pathogenic mechanisms underlining the mutations of DES and LMNA, but also offered a new human-cardiomyocytes based platform for drug testing.
- Tse, H.,F., Ho, J.,C, Choi, S.,W., Lee, Y.,K., Butler, A.,W., Ng, K.,M., Siu, C.,W., Simpson, M.,A., Lai, W.,H., Chan, Y.,C., Au, K.,W., Zhang, J., Lay, K.,W., Esteban, M.,A., Nicholls, J.,M., Colman, A., Sham, P.C. (2013) Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet 22:1395-1403
- Siu, C.,W., Lee, Y.,K., Ho, J.,C., Lai, W.,H., Chan, Y.,C., Ng, K.,M., Wong, L.,Y., Au, K.,W., Lau, Y.,M., Zhang, J., Lay, K.,W., Colman, A., Tse, H.,F. (2012) Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY). 4:803-822.
- Ng, K.,M., Tse, H.,F. (2012) Modeling Hereditary Cardiac Disease with Patient Specific Induced Pluripotent Stem Cells: Opportunities and Concerns. J Cardiovasc Pharmacol 60:406-407
- Li, W., Wang, X., Fan, W., Zhao, P., Chan, Y.,C., Chen, S., Zhang, S., Guo, X., Zhang, Y., Li, Y., Cai, J., Qin, D., Li, X., Yang, J., Peng, T., Zychlinski, D., Hoffmann, D., Zhang, R., Deng, K., Ng, K.,M., Menten, B., Zhong M, Wu J, Li Z, Chen Y, Schambach A, Tse HF, Pei D, Esteban MA. (2012) Modeling Abnormal Early Development with Induced Pluripotent Stem Cells from Aneuploid Syndromes. Hum Mol Genet 21:32-45.
- Lee, Y., K., Ng, K.,M., Lai, W.,H., Chan, Y.,C., Lau, Y.,M., Lian, Q., Tse,H.,F., Siu, C.,W.(2011) Calcium Homeostasis in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cell Rev 7:976-986
- Ng, K.,M., Lee, Y.K., Lai, W.H., Chan, Y.C., Fung, M.,L., Tse, H.F., Siu, C.,W. (2011) Exogenous expression of Human apoA-I Enhances Cardiac Differentiation of Pluripotent Stem Cells. PLoS One. 6:e19787
- Zhou, T., Benda, C., Duzinger, S., Huang, Y., Li, X., Li, Y., Gui, X., Cao, G., Chen, S., Chan, Y.,C., Ng, K.M., Ho, J.,C., Wieser, M., Wu, J., Redl, H., Tse, H.,F., Grillari-Voglaue, R., Grillari, J., Pei, D., Esteban,. M., A. (2011) Reprogramming of human urine cells to induced pluripotent stem cells. J Am Soc Nephrol. 22:1221-1228
- Ng, K.,M., Lee, Y.,K., Chan, Y.,C., Lai, W.,H., Fung, M.,L., Li, R.,A., Siu, C.,W., Tse. H.,F. (2010) Exogenous expression of HIF-1 alpha promotes cardiac differentiation of embryonic stem cells. J Mol Cell Cardiol. 48:1129-37
2013: General Research Fund (GRF): Novel Therapeutic Approach for X-linked related Danon Disease~ Insight from Patient-specific Pluripotent Stem Cells Platform. (HKU 775613M HKD 952,636)